Cargando…

Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia

To determine the potential benefits and feasibility of administering maintenance therapy with dinutuximab beta for high-risk neuroblastoma (HRNB) in clinical practice, a retrospective review of charts of patients with HRNB treated at a single center in Croatia (2012–2021) was undertaken. Of 23 patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giljević, Jasminka Stepan, Rajačić, Nada, Mikulić, Danko, Batoš, Ana Tripalo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318789/ https://www.ncbi.nlm.nih.gov/pubmed/35883927 http://dx.doi.org/10.3390/children9070943

Ejemplares similares

MEDB-20. The outcome of medulloblastoma patients in the 2010-2018 period in Children’s Hospital Zagreb
por: Jadrijevic-Cvrlje, Filip, et al.
Publicado: (2022)

Dinutuximab beta for neuroblastoma
Publicado: (2020)

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
por: Olgun, Nur, et al.
Publicado: (2022)

Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
por: Ehlert, Karoline, et al.
Publicado: (2020)

Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
por: Spasov, Neofit, et al.
Publicado: (2021)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma
por: Launspach, Michael, et al.
Publicado: (2021)

Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma
por: Balaguer, Julia, et al.
Publicado: (2022)

INVASIVE FUNGAL INFECTIONS IN CHILDREN TREATED FOR HEMATOLOGIC MALIGNANCIES – A FIVE-YEAR SINGLE CENTER EXPERIENCE
por: Buljan, Domagoj, et al.
Publicado: (2022)

Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance
por: Barone, Giuseppe, et al.
Publicado: (2021)

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
por: Wieczorek, Aleksandra, et al.
Publicado: (2022)

Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava
por: Achbergerová, Monika, et al.
Publicado: (2022)

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
por: Lode, Holger N., et al.
Publicado: (2023)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
por: Cicek, Filiz, et al.
Publicado: (2020)

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
por: Keyel, Michelle E, et al.
Publicado: (2018)

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
por: Ladenstein, Ruth, et al.
Publicado: (2020)

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2021)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction
por: Cupit-Link, Margaret, et al.
Publicado: (2023)

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

Quantification of total dinutuximab concentrations in neuroblastoma patients with liquid chromatography tandem mass spectrometry
por: El Amrani, Mohsin, et al.
Publicado: (2018)

Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients
por: Mastrangelo, Stefano, et al.
Publicado: (2021)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
por: Troschke-Meurer, Sascha, et al.
Publicado: (2023)

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse
por: Flaadt, Tim, et al.
Publicado: (2023)

Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model
por: Ornell, Kimberly J., et al.
Publicado: (2020)

Hepatitis E Virus in Croatia in the “One-Health” Context
por: Mrzljak, Anna, et al.
Publicado: (2021)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
por: Martínez-Sanz, Paula, et al.
Publicado: (2021)

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

Neglected tuberculous trochanteric bursitis in an adolescent girl: A case report and literature review
por: Vlaic, Josip, et al.
Publicado: (2021)

Neurodevelopmental disorder caused by an inherited novel KMT5B variant: case report
por: Odak, Ljubica, et al.
Publicado: (2023)

Malignant Peripheral Nerve Sheath Tumor of the Inguinum and Angiosarcoma of the Scalp in a Child with Neurofibromatosis Type 1
por: Milković Periša, Marija, et al.
Publicado: (2017)

Achromobacter xylosoxidans Purulent Bronchitis in a Previously Healthy Child: An Unexpected Consequence of COVID-19 Infection
por: Matijasic, Nusa, et al.
Publicado: (2022)

Impact of an exercise program in children with inflammatory bowel disease in remission
por: Trivić, Ivana, et al.
Publicado: (2022)

A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood
por: Keyel, Michelle E., et al.
Publicado: (2023)

Retroperitoneal Paraganglioma Treated With Tumor Resection and Replacement of the Inferior Vena Cava
por: Đapić, Krešimir, et al.
Publicado: (2023)

Lemierre Syndrome in Adolescent with Active Ulcerative Colitis
por: Unić, Josipa, et al.
Publicado: (2018)

Magnetic Resonance Imaging Can Be Used to Assess Sarcopenia in Children with Newly Diagnosed Crohn’s Disease
por: Blagec, Paola, et al.
Publicado: (2023)

Complementary Medicine Practice and Use of Dietary Supplements in Pediatric Cancer Patients in Croatia
por: Kranjcec, Izabela, et al.
Publicado: (2022)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
por: Lode, Holger N., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rjji8igfe2uqp5vhtquafhdl55